Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis

被引：0
|
作者：
Liu, Sijia [1 ]
Ma, Jialao [2 ,3 ,4 ]
机构：
[1] Sun Yat Sen Univ, Sch Law, Guangzhou, Peoples R China
[2] Guangdong Polytech Normal Univ, Sch Law & Intellectual Property, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Guangzhou Peoples Hosp 12, Guangzhou, Peoples R China
[4] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou 511495, Peoples R China
来源：
LANCET RHEUMATOLOGY | 2025年 / 7卷 / 03期
关键词：
D O I：
10.1016/S2665-9913(25)00028-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e159 / e159
页数：1
相关论文
共 50 条
  • [1] RISK OF HERPES ZOSTER IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER BIOLOGICAL, TARGETED SYNTHETIC, AND CONVENTIONAL SYNTHETIC DMARD TREATMENT
    Strangfeld, A.
    Redeker, I.
    Kekow, J.
    Burmester, G. R.
    Braun, J.
    Zink, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 150 - 151
  • [2] COST-EFFECTIVENESS OF ADVANCED THERAPIES INITIATION IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SPAIN, WHO FAILED A CONVENTIONAL SYNTHETIC DMARD VERSUSA FIRST BIOLOGICAL DMARD
    Balsa, A.
    Fernandez, L. Silva
    Sanmarti, R.
    Valderrama, M.
    Montoro, M.
    Juste, A. De Lossada
    VALUE IN HEALTH, 2024, 27 (12)
  • [3] Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
    Russell, Mark
    Gibson, Mark
    Zuckerman, Benjamin
    Kumar, Kanta
    Dubey, Shirish
    Adas, Maryam
    Alveyn, Edward
    Patel, Samir
    Yang, Zijing
    Bechman, Katie
    Price, Elizabeth
    Gallagher, Sarah
    Cope, Andrew
    Norton, Sam
    Galloway, James
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5187 - 5188
  • [4] SURVIVAL OF SYNTHETIC AND BIOLOGICAL DMARD THERAPY IN RHEUMATOID ARTHRITIS: RESULTS OF DAILY CLINICAL PRACTICE
    Rojas-Zuleta, W. G.
    Pantoja-Marquez, A. E.
    Vasquez, M.
    Duque-Zapata, N.
    Orozco, C.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S75 - S75
  • [5] Rheumatoid factor and the initiation of DMARD therapy in patients with early rheumatoid arthritis
    Nikolaisen, C
    Kvien, TK
    Mikkelsen, K
    Kaufmann, C
    Ridevand, E
    Nossent, HC
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 195 - 195
  • [6] Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis
    Mcdermott, Gregory C.
    Diiorio, Michael
    Kawano, Yumeko
    Jeffway, Mary
    Macvicar, Megan
    Dahal, Kumar
    Moon, Su-Jin
    Seyok, Thany
    Coblyn, Jonathan
    Massarotti, Elena
    Weinblatt, Michael E.
    Weisenfeld, Dana
    Liao, Katherine P.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 66
  • [7] Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
    Burkard, Theresa
    Williams, Ross D.
    Vallejo-Yaguee, Enriqueta
    Huegle, Thomas
    Finckh, Axel
    Kyburz, Diego
    Burden, Andrea M.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (03)
  • [8] Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis
    Orsolini, Giovanni
    Fassio, Angelo
    Rossini, Maurizio
    Adami, Giovanni
    Giollo, Alessandro
    Caimmi, Cristian
    Idolazzi, Luca
    Viapiana, Ombretta
    Gatti, Davide
    PHARMACOLOGICAL RESEARCH, 2019, 147
  • [9] Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
    Singh, Namrata
    Gold, Laura
    Wysham, Katherine
    Andrews, James
    Reid, Pankti
    Makris, Una
    England, Bryant
    Lee, Jiha
    George, Michael
    Baker, Joshua
    Jarvik, Jeffrey
    Heagerty, Patrick
    Singh, Siddharth
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4404 - 4406
  • [10] A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
    Cappelli, Laura C.
    Reed, George
    Pappas, Dimitrios A.
    Kremer, Joel M.
    RHEUMATOLOGY AND THERAPY, 2023, 10 (6) : 1669 - 1681
12345